Advanced Search

Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2002 June;54(2) > Minerva Urologica e Nefrologica 2002 June;54(2):93-106

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536

Frequency: Bi-Monthly

ISSN 0393-2249

Online ISSN 1827-1758

 

Minerva Urologica e Nefrologica 2002 June;54(2):93-106

    REVIEWS

Anti-viral drugs in continuous ambulatory peritoneal dialysis (CAPD)

Izzedine H., Launay-Vacher V., Issad B., Deray G.

From the Department of Nephrology, Pitie Salpetriere Hospital - Paris, France

The prevalence of HIV-positive subjects in dialysis (hemodialysis and peritoneal dialysis) population varies from 0.13 to 0.36% in italian and french studies, respectively. Most drugs used in HIV therapy are primarly excreted by the kidney. In patients with renal insufficiency, careful dosage adjustment is mandatory to optimize drug exposure and reduce the risk for adverse events. We review the impact of peritoneal dialysis on the pharmacokinetics of antiviral drugs, and discuss on the dosage recommandations needed to achieve efficacy and avoid toxicity in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis (CAPD).

language: English


FULL TEXT  REPRINTS

top of page